Harrow Health, Inc.

NASDAQ:HROW

Drug Manufacturers - Specialty & Generic

Healthcare
$32.16 +0.29%

+$0.12 today

Market cap
$1.21B
Beta
0.28
P/E (TTM)
-104.7
EPS (TTM)
-$0.40
52W Low $28.54High $54.85

Volume 0.87M

Average 0.75M

HROW Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Harrow Health, Inc.NASDAQ: HROW

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 61.2%

Gross margin was 61.2% in Q1 FY2026, down 6.4 pp from a year earlier. On a trailing-twelve-month basis it was 74.1%, down 0.4 pp year over year. Over 3 fiscal years it widened by 3.7 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
61.2%-18.1 pp QoQ
Last fiscal yearDec 2025
75.1%-0.3 pp YoY
LTMMar 2026
74.1%-0.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-6.4 pp——
1 year-0.3 pp——
3 years+3.7 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
75.1%
Year-over-year change
-0.3pp

Gross Margin vs competitors

How HROW compares with its peers on the latest reported figures

  • HROW's LTM Mar 2026 gross margin of 74.1% is the 3rd highest of the 7 companies compared; the peer median is 28.9%.
  • Its year-over-year change of -0.4 pp is the 2nd highest of 6, against a peer median of -16.8 pp.
  • Over three fiscal years its change of +3.7 pp compares with a peer median of -3.5 pp.
HROW Competitors Peer median
Gross Margin for HROW and competitors
Company Period LTM level YoY 3-year change
OCULOcular Therapeutix, Inc.LTM Mar 202687.2% -3.4 pp-3.9 pp
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 202676.5% -16.8 pp+13.5 pp
HROWHarrow Health, Inc.LTM Mar 202674.1% -0.4 pp+3.7 pp
BLCOBausch + Lomb CorporationLTM Jun 202657.2% +0.3 pp-4.9 pp
TARSTarsus Pharmaceuticals, Inc.LTM Sep 20260.5% -88.3 pp-3.1 pp
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-360.9% -377.1 pp—
OCSOculis Holding AGLTM Mar 2026-2889.4% ——
KODKodiak Sciences Inc.FY2025— ——
TTRXTurn Therapeutics Inc.FY2025— ——
Peer median (excluding HROW) 28.9%-16.8 pp-3.5 pp

Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue72.48M88.6M130.19M199.61M272.3M
Cost of Revenue18.21M25.38M39.64M49.25M67.93M
Gross Profit54.26M63.21M90.55M150.37M204.37M
Gross Margin74.9%71.3%69.6%75.3%75.1%
Research & Development11.08M3.05M6.65M12.23M12.85M
Selling, General & Admin39.82M000152.91M
Operating Expenses52.65M61.29M90.12M141.55M165.76M
Depreciation & Amortization1.74M2.83M11.14M13.05M18.91M
EBITDA5.1M(3.94M)11.95M22.13M41.36M
EBITDA Margin7.0%-4.4%9.2%11.1%15.2%
Operating Income1.61M1.92M431K8.82M38.61M
Operating Margin2.2%2.2%0.3%4.4%14.2%
Interest Income00000
Interest Expense5.44M7.24M21.32M22.79M24.18M
Other Income / Expenses(19.49M)(15.93M)(24.14M)(26.14M)(40.33M)
Income Before Tax(17.87M)(14.01M)(23.71M)(17.32M)(1.72M)
Pre-Tax Margin-24.7%-15.8%-18.2%-8.7%-0.6%
Income Tax Expense133K75K701K161K3.42M
Net Income(18.01M)(14.09M)(24.41M)(17.48M)(5.14M)
Net Margin-24.8%-15.9%-18.7%-8.8%-1.9%
EPS (Basic)(0.69)(0.51)(0.75)(0.49)(0.14)
EPS (Diluted)(0.69)(0.51)(0.75)(0.49)(0.14)
Weighted Avg Shares26.76M27.46M32.62M35.65M36.76M
Weighted Avg Shares (Diluted)26.76M27.46M32.62M35.65M36.76M

Harrow Health, Inc.

NASDAQ:HROW

Intrinsic Alpha fair value

Locked

Current Price

$32.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.